D. Boral Capital Reiterates “Buy” Rating for Plus Therapeutics (NASDAQ:PSTV)

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $5.00 price target on the stock.

PSTV has been the subject of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Wednesday, October 8th. Zacks Research cut Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Ascendiant Capital Markets dropped their target price on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, November 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Plus Therapeutics in a report on Wednesday, November 26th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Plus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $7.25.

Plus Therapeutics Trading Down 5.1%

Plus Therapeutics stock opened at $0.56 on Thursday. The firm has a market capitalization of $76.30 million, a P/E ratio of -0.29 and a beta of 0.85. The business has a 50-day moving average of $0.57 and a 200-day moving average of $0.54. Plus Therapeutics has a 1 year low of $0.16 and a 1 year high of $2.31.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Thursday, October 30th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $1.40 million for the quarter, compared to analyst estimates of $1.50 million. Research analysts anticipate that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Plus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Scientech Research LLC acquired a new position in shares of Plus Therapeutics during the 3rd quarter worth about $100,000. Susquehanna International Group LLP bought a new stake in Plus Therapeutics during the third quarter worth about $46,000. Jane Street Group LLC acquired a new position in Plus Therapeutics during the second quarter valued at approximately $41,000. Finally, Altium Capital Management LLC bought a new position in Plus Therapeutics in the third quarter valued at approximately $628,000. 3.28% of the stock is currently owned by institutional investors and hedge funds.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.